Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Vaccine
; 24(27-28): 5571-83, 2006 Jul 07.
Article
em En
| MEDLINE
| ID: mdl-16753240
ABSTRACT
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were approximately 12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Papillomaviridae
/
Vacinas Virais
/
Vacinas contra Papillomavirus
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Brasil